<DOC>
	<DOCNO>NCT00402948</DOCNO>
	<brief_summary>This study evaluate efficacy , safety tolerability two dosages new drug TPI ASM8 administer inhalation 14 day mild moderate asthmatic patient , age 18-65 , non-smokers . The study also look nature quantity inflammatory white cell lung secretion blood , additional inflammation marker .</brief_summary>
	<brief_title>Safety Efficacy Two Dosages Inhaled TPI ASM8 Compared Placebo Mild Moderate Asthmatic Patients</brief_title>
	<detailed_description>See</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<criteria>Age 1865 y. old , non exsmokers &gt; 6 month Mild moderate asthmatic general good health On either lowdose inhaled corticosteroid steroid naive No asthma medication Regular sputum producer EOS 3 % randomization , FEV1 &gt; 70 % Respiratory infection within last 4 week Any condition may affect conduct study per investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>High eosinophil level sputum</keyword>
</DOC>